AKT1 and breast carcinoma: Western blots revealed that, although there were no apparent differences in total Akt levels between control and α-mangostin-treated mammary carcinoma cells, phospho-Akt-Thr308 was lower in mammary carcinoma cells treated with α-mangostin for 24 hours (Figure 7B).